CellSource Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Takashi Sawada

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	1.3yrs
Board average tenure	2.3yrs

Recent management updates

Recent updates

CEO

Takashi Sawada (66 yo)

less than a year

Tenure

Mr. Takashi Sawada serves as Representative Director, President and CEO at CellSource Co., Ltd since January 25, 2024. He served as Independent Outside Director at CellSource Co., Ltd since January 2022 un...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Masayuki Yamakawa	Executive Chairman & MD	2.3yrs	no data	36.22% ¥ 10.8b
Takashi Sawada	Representative Director	less than a year	no data	no data
Masato Tsumamoto	Representative Director & Chief Transformation Officer	less than a year	no data	6.85% ¥ 2.0b
Hirohiko Hanaki	Executive Officer & Head of Medical Affairs Headquarters	7.3yrs	no data	0.36% ¥ 108.8m
Katsuji Onishi	Executive Officer	2.3yrs	no data	no data
Kaoru Hosoda	Executive Officer & Head of Corporate Planning Headquarters	1.3yrs	no data	no data
Futa Asada	Executive Officer & Head of CPC Headquarters	1.3yrs	no data	no data

1.3yrs

Average Tenure

53yo

Average Age

Experienced Management: 4880's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Masayuki Yamakawa	Executive Chairman & MD	2.3yrs	no data	36.22% ¥ 10.8b
Takashi Sawada	Representative Director	2.3yrs	no data	no data
Masato Tsumamoto	Representative Director & Chief Transformation Officer	less than a year	no data	6.85% ¥ 2.0b
Hirohiko Hanaki	Executive Officer & Head of Medical Affairs Headquarters	7.3yrs	no data	0.36% ¥ 108.8m
Kumi Fujisawa	Independent Outside Director	1.3yrs	no data	0.0045% ¥ 1.4m
Norio Murakami	Independent Outside Director	6.6yrs	no data	no data
Takeshi Amemiya	Director	6.8yrs	no data	0.32% ¥ 94.7m
Tsuneyasu Ozaki	Independent Outside Director	1.3yrs	no data	no data

2.3yrs

Average Tenure

57.5yo

Average Age

Experienced Board: 4880's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

CellSource Management

Management criteria checks 0/4

Key information

Recent management updates

Less than half of directors are independent

CellSource Co., Ltd., Annual General Meeting, Jan 25, 2024

CellSource Co., Ltd., Annual General Meeting, Jan 27, 2023

Less than half of directors are independent

Less than half of directors are independent

Less than half of directors are independent

Recent updates

First quarter 2024 earnings released: EPS: JP¥7.23 (vs JP¥11.56 in 1Q 2023)

Investor sentiment improves as stock rises 16%

CellSource Co., Ltd. to Report Q2, 2024 Results on Jun 13, 2024

Less than half of directors are independent

Now 20% undervalued after recent price drop

CellSource Co., Ltd. to Report Q1, 2024 Results on Mar 11, 2024

Now 21% undervalued after recent price drop

Now 24% undervalued after recent price drop

Investor sentiment deteriorates as stock falls 20%

Full year 2023 earnings released: EPS: JP¥48.88 (vs JP¥54.50 in FY 2022)

CellSource Co., Ltd., Annual General Meeting, Jan 25, 2024

CellSource Co., Ltd. to Report Fiscal Year 2023 Results on Dec 15, 2023

New minor risk - Shareholder dilution

Third quarter 2023 earnings released: EPS: JP¥14.03 (vs JP¥15.05 in 3Q 2022)

New minor risk - Shareholder dilution

CellSource Co., Ltd. to Report Q3, 2023 Results on Sep 13, 2023

New major risk - Share price stability

Second quarter 2023 earnings released: EPS: JP¥10.38 (vs JP¥8.20 in 2Q 2022)

Cellsource Co., Ltd. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending October 31, 2023

First quarter 2023 earnings released: EPS: JP¥11.56 (vs JP¥8.32 in 1Q 2022)

Full year 2022 earnings released: EPS: JP¥54.50 (vs JP¥105 in FY 2021)

CellSource Co., Ltd. to Report Q1, 2023 Results on Mar 14, 2023

Investor sentiment deteriorated over the past week

Full year 2022 earnings released: EPS: JP¥54.50 (vs JP¥105 in FY 2021)

CellSource Co., Ltd. Provides Earnings Guidance for the Fiscal Year Ending October 31, 2023

CellSource Co., Ltd., Annual General Meeting, Jan 27, 2023

Less than half of directors are independent

CellSource Co., Ltd. to Report Q4, 2022 Results on Dec 14, 2022

Third quarter 2022 earnings released: EPS: JP¥15.05 (vs JP¥25.88 in 3Q 2021)

Second quarter 2022 earnings released: EPS: JP¥8.20 (vs JP¥25.12 in 2Q 2021)

Less than half of directors are independent

CellSource Co., Ltd. to Report Q2, 2022 Results on Jun 13, 2022

Investor sentiment deteriorated over the past week

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Now 23% undervalued after recent price drop

Now 21% undervalued after recent price drop

Less than half of directors are independent

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2021 earnings released: EPS JP¥25.12 (vs JP¥19.81 in 2Q 2020)

First quarter 2021 earnings released: EPS JP¥18.38 (vs JP¥36.57 in 1Q 2020)

CYBERDYNE Inc Forms Strategic Partnership with Cellsource Co., Ltd

Full year 2020 earnings released: EPS JP¥137 (vs JP¥137 in FY 2019)

CellSource Co., Ltd. to Report Q1, 2021 Results on Mar 15, 2021

CellSource Co., Ltd., Annual General Meeting, Jan 28, 2021

CellSource Co., Ltd. to Report Q3, 2020 Results on Sep 10, 2020

CEO

Tenure

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age